IPO registrations (S-1, F-1) · Registrants
TAO Synergies Inc.
- SEC CIK
- 1571934 · filings on EDGAR ↗
- Name on the registration
- Synaptogenix, Inc.
- Former names
- Synaptogenix, Inc. (2020–2025); NEUROTROPE BIOSCIENCE, INC. (2013–2020)
- Registration
- Form S-1, first filed 2020-10-09, last 2021-07-02; 3 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2020-11-12; declared effective 2020-11-09
- Industry (SIC)
- Finance Services 6199
- Incorporated in
- DE
- Business address
- 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, New York, NY 10036
- EIN
- 46-1585656
- Ticker
- TAOX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- TAO Synergies Inc. on the corporate pages
Offering terms
- Final price
- $49.43 per share (424B1 filed 2020-11-12)
- Shares sold
- 8,969,340
- Gross proceeds
- $443,354,476 before underwriting discounts and any over-allotment option
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: TAO Synergies Inc. EXACT (CIK (EXACT))
- SEC filer: Synaptogenix, Inc. EXACT (CIK (EXACT))
- Person page: Alan J Tuchman Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 13
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-10-09 | S-1 | S-1 (registration) | NEUROTROPE BIOSCIENCE, INC. | 0001104659-20-113989 ↗ |
| 2020-10-30 | S-1/A | S-1/A (amendment) | NEUROTROPE BIOSCIENCE, INC. | 0001104659-20-119650 ↗ |
| 2020-11-05 | S-1/A | S-1/A (amendment) | NEUROTROPE BIOSCIENCE, INC. | 0001104659-20-121818 ↗ |
| 2020-11-09 | EFFECT | EFFECT (declared effective) | NEUROTROPE BIOSCIENCE, INC. | 9999999995-20-003107 ↗ |
| 2020-11-12 | 424B1 | 424B1 (final prospectus) | NEUROTROPE BIOSCIENCE, INC. | 0001104659-20-124494 ↗ |
| 2021-02-08 | S-1 | S-1 (registration) | Synaptogenix, Inc. | 0001104659-21-013212 ↗ |
| 2021-04-13 | S-1/A | S-1/A (amendment) | Synaptogenix, Inc. | 0001104659-21-049814 ↗ |
| 2021-04-29 | EFFECT | EFFECT (declared effective) | Synaptogenix, Inc. | 9999999995-21-001624 ↗ |
| 2021-06-24 | S-1 | S-1 (registration) | Synaptogenix, Inc. | 0001104659-21-085173 ↗ |
| 2021-07-02 | S-1/A | S-1/A (amendment) | Synaptogenix, Inc. | 0001104659-21-088933 ↗ |
| 2021-07-06 | EFFECT | EFFECT (declared effective) | Synaptogenix, Inc. | 9999999995-21-002654 ↗ |
| 2022-04-27 | EFFECT | EFFECT (declared effective) | Synaptogenix, Inc. | 9999999995-22-001127 ↗ |
| 2022-12-27 | EFFECT | EFFECT (declared effective) | Synaptogenix, Inc. | 9999999995-22-003646 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-11-05 | S-1/A | registration statement | $49.43 | 8,969,340 | $443,354,476 | 0 | primary document; price line, shares headline, proceeds computed | document ↗ | ||
| 2020-11-12 | 424B1 | final prospectus | $49.43 | 8,969,340 | $443,354,476 | 0 | primary document; price line, shares headline, proceeds computed | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Alkon Daniel L. | Director,Officer | Chief Scientific Officer; President and CSO; See Remark; See Remarks | 7 | 2021–2022 | |
| Bernstein Bruce | Director | 14 | 2021–2026 | ||
| Perry George | Director | 2 | 2021 | ||
| SCHECHTER JONATHAN | Director | 12 | 2021–2025 | ||
| Silverman Joshua | Director; Director,Officer | Executive Chairman | 14 | 2021–2026 | |
| Singer William S. | Director | 14 | 2021–2026 | ||
| TUCHMAN ALAN J | Director,Officer | Chief Executive Officer; Chief Medical Officer | 8 | 2021–2026 | person page Fuzzy |
| WEINSTEIN ROBERT | Officer | Chief Financial Officer | 8 | 2021–2026 | |
| Ephron Robert | Director | 4 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-10-24 | TAO Synergies Inc. | Other | $11,000,000 | $11,000,000 | 7 | 1 |
| 2025-06-23 | Synaptogenix, Inc. | Biotechnology | $5,500,000 | $5,500,000 | 5 | 1 |
| 2024-09-23 | Synaptogenix, Inc. | Biotechnology | $3,207,000 | $3,207,000 | 4 | 1 |
| 2021-06-29 | Synaptogenix, Inc. | Biotechnology | $12,477,342 | $12,477,342 | 14 | 1 |
| 2021-02-12 | Synaptogenix, Inc. | Biotechnology | $14,003,334 | $14,003,334 | 66 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | TAO Synergies Inc. | NY | Form D private offerings | CIK (EXACT) |
| SEC filer | TAO Synergies Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | Alan J Tuchman | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Finance Services, NY first:
- OFFITBANK HOLDINGS INC NY
- Lazard Group Finance LLC NY
- Tiptree Financial Partners, L.P. NY
- MAP FINANCIAL GROUP, INC. NY
- LOANIO, INC. NY
- Chaince Digital Holdings Inc. NY
- CAPSTONE FINANCIAL GROUP, INC. NY
- Easterly Acquisition Corp. NY
- Coinbase Global, Inc. NY
- Migom Global Corp. NY
In other datasets, the same topic (Finance) in NY:
- Lobbying client: 3B1 PARTNERS (Federal lobbying (LDA))
Interests: Finance Services · Finance